A behavioral walking program matched supervised aerobic training for improving asthma control in a randomized trial of physically inactive adults.
|Articles|March 30, 2022
- March 2022
- Volume 88
- Issue 3
Pet Peeves: March 2022
Brought to you by the Sassy Pharmacist
Advertisement
ASAP With an Attitude
When pharmacists ask patients when they would like to pick up their prescriptions, and they say, “now” or “as soon as it is ready.”
No Can Do
When a patient comes to the pharmacy to refund a front-end item.
Early Arrival
When patients show up at the pharmacy before it opens, expecting their prescriptions to have been filled overnight.
What’s Bothering You?
Bossy patients, abandoned prescriptions, drive-through demands? We want to know! Send your pet peeves to cmollison@pharmacytimes.com. We’ll share them here and online.
Articles in this issue
over 4 years ago
Case Studies: March 2022over 4 years ago
OTC Product News: March 2022over 4 years ago
Vuity From Allerganover 4 years ago
Skinny Labeling Allows More Drugs to Enter the Marketover 4 years ago
Flexible Practice Models Can Expand Patient Care Servicesover 4 years ago
March 2022 Rx Product Newsover 4 years ago
Pharmacist Imposter Flees PremisesAdvertisement
Related to this article
Phase 2b data from EASD 2026 show the amylin-incretin combination also cut HbA1c by up to 2.9% in adults with obesity or overweight and type 2 diabetes.
American Pharmacists Month kicked off on October 1, honoring more than 700,000 pharmacy professionals and 250 years of caring for America's communities.
fMRI data show cagrilintide-semaglutide altered brain responses to high-calorie food cues; REIMAGINE analyses point to ectopic fat and bone effects.
A pharmacist-led collaborative drug therapy management program at NYC Health + Hospitals/Bellevue reported high patient satisfaction, and every surveyed patient said they felt respected and supported by their pharmacist.
A Novo Nordisk–funded claims analysis of adults with type 2 diabetes found an adjusted HR of 1.06 for MACE with switching, although the findings cannot show causation.
Invasive pneumococcal disease may be the first sign of undiagnosed blood cancers and antibody deficiencies in adults, a new study finds.
A new analysis finds a significant weight loss edge for tirzepatide under one estimand but not another; no head-to-head trial exists at these doses.
Advertisement
Advertisement
Trending on Pharmacy Times
1
Pharmacists Key to Lp(a) Counseling and Lipid Optimization
2
EloraTZP Delivers Up to 23.3% Weight Loss in Adults With Obesity and T2D
3
Why Lp(a) Testing Lagged Behind LDL Cholesterol Screening
4
Semaglutide 2 mg Tied to Lower MACE Risk Than Tirzepatide Switch
5